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Abstract
Background: Previous studies have found associations between the use of central nervous system medication and
the risk of cognitive decline in the aged. Our aim was to assess whether the use of a single central nervous system
(CNS) medication and, on the other hand, the combined use of multiple CNS medications over time are related to
the risk of cognitive decline in an older (≥ 65 yrs) population that is cognitively intact at baseline.
Methods: We conducted a longitudinal population-based study of cognitively intact older adults. The participants
were 65 years old or older and had Mini-Mental State Examination (MMSE) sum scores of 24 points or higher. The
study included a 7.6-year follow-up. The use of benzodiazepines and related drugs (BZDs), antipsychotics (APs),
antidepressants (ADs), opioids (Ops), anticholinergics (AChs) and antiepileptics (AEs) was determined at baseline
and after a 7.6-years of the follow-up period. Cognitive functioning was used as an outcome variable measured
with MMSE at baseline and at the mean follow-up of 7.6 years. Control variables were adjusted with analyses of
covariance.
Results: After adjusting for control variables, the use of Ops and the concomitant use of Ops and BZDs as well as
the use of Ops and any CNS medication were associated with cognitive decline. The use of AChs was associated
with decline in cognitive functioning only in men.
Conclusions: Of all the CNS medications analyzed in this study, the use of Ops may have the greatest effect on
cognitive functioning in the ageing population. Due to small sample sizes these findings cannot be generalized to
the unselected ageing population. More studies are needed concerning the long-term use of CNS medications,
especially their concomitant use, and their potential cognitive effects.
Background
Epidemiological studies have produced evidence of the
relationship between the use of psychotropic drugs and
the risk of cognitive decline in the aged populations
[1,2]. Long-term use of benzodiazepines (BZDs) has
been suggested to increase the risk of cognitive decline
or dementia in the aged [3-6]. It has also been suggested
that the use of anticholinergic medications (AChs) may
be related to the risk of cognitive deterioration in the
aged [7-11].
A majority of the studies have examined the association
between a single group of medications with effects on the
central nervous system (CNS) and cognitive decline. Our
literature search in PubMed produced only one study [2]
about the concomitant use of several CNS medications
and the risk of cognitive decline. The results of the study
showed that the combined use of CNS medications was
associated with cognitive decline in older adults who
were cognitively intact at baseline [2].
We decided to test the hypothesis whether the use of
one CNS medication or, in particular, the use of a com-
bination of two or more CNS medications predict
decline in cognitive functioning among older persons
who are cognitively healthy at baseline.
Methods
Participants
The sample of this longitudinal population-based study
comprised participants of the longitudinal Lieto study.
The population in the first phase of the Lieto study
* Correspondence: juhpuu@utu.fi
1Department of Family Medicine, University of Turku, Turku, Finland
Full list of author information is available at the end of the article
Puustinen et al. BMC Geriatrics 2011, 11:70
http://www.biomedcentral.com/1471-2318/11/70
© 2011 Puustinen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.consisted of all the residents in the municipality of Lieto
born in 1926 or earlier (N = 1,283) being aged 65 or
older in the study year. Of these, 1,196 (93%, 488 men
and 708 women) participated [12-15]. The sample of
our study comprised the participants of the first phase
of the Lieto study [12-15] who scored 24 to 30 sum
points in the Mini-Mental State Examination (MMSE)
[16] and who were alive and participated in the second
phase of the longitudinal Lieto study (N = 565; 227 men
and 338 women). The first phase of the Lieto study was
carried out between 1 October, 1990, and 31 December,
1991, and the second phase between 1 March, 1998, and
31 September, 1999 [12-15]. Thus, the mean follow-up
time was 7.6 ± 0.5 years (range 6.4-9.1 years).
Methods and measures
During both phases of the Lieto study all participants
were interviewed about their socioeconomic back-
ground, physical and psychosocial factors, functional
abilities, use of medications and health behaviour. They
were also clinically examined by a health centre physi-
cian who was part of the research team (RI or ML).
Clinical tests were performed by a trained research
nurse. Medical records in the Härkätie Health Centre,
Lieto, were used in recording previous diagnoses. Simi-
lar measures were used in both phases.
Cognitive functioning was measured during both
phases with an MMSE performed by a trained nurse.
The MMSE scale consists of 23 items, and the sum
score ranges from 0 to 30, higher scores indicating bet-
ter cognitive performance [16]. The mean change in
MMSE sum scores during the follow-up was used as an
outcome variable.
Information about the use of all medications prior to
seven days before the interview was collected in a perso-
nal interview conducted by a trained nurse at the base-
line and follow-up interviews to describe the total
medication at both data collection phases. The partici-
pants had been informed to bring along their prescrip-
tion forms and medications in order to confirm their
current use of medication. A health centre physician
from the research team (RI or ML) verified the medica-
tions from medical records. In cases where the person
interviewed was unable to answer questions adequately,
a close relative or caregiver provided the relevant infor-
mation. If the participant was unable to visit the health
centre, a trained nurse made a home visit to check the
medications. All the prescribed medications (both regu-
lar and irregular) and non-prescribed medications (vita-
mins etc.) were taken into account.
Medications were defined by using the Anatomical
Therapeutic Chemical (ATC) Classification (1996) [17].
The groups of medications defined as those with an
effect on the central nervous system (CNS) and used in
the analyses of this study were as follows: benzodiaze-
pines and related drugs (BZDs) (ATC codes N05BA,
N05CD, N03AE01, N05CF, A03CA, C01DA70,
M05AA51, N06CA01, N02BA71), antipsychotics (APs)
(ATC codes N05A, N06CA01), antidepressants (ADs)
(ATC codes N06A, N06CA), opioids (Ops) (ATC codes
N01AH, N02A, N02BE51, R05DA, R05FA), anticholiner-
gic medications (AChs) (ATC codes N04A, N05AA01,
N05AA02, N05AB01, N05AB02, N05AB03, N05AB04,
N05AC01, N05AC02, N05AF01, N05AF03, N05AF05,
N05BB01, N06AA04, N06AA06, N06AA09, N06AA12,
102AG, A03AA, A03AB, A03AX03, A03B, A03CA,
A03CB31, A03DA, A03FA01, A04AD01, A04AD12,
C01BA01, C01BA03, C01BA51, C01BA71, R03BB,
M03B, G04BD, S01FA, R01BA01, R01BA51, R06AB01,
R06AE03, R06AE53) and antiepileptic medications (AEs)
(ATC code N03A) [18,19].
The usages of these groups of CNS medications were
first dichotomized (regular or irregular use vs. no use).
The doses of the medications were not taken into
account. Eight variables describing the use of CNS med-
ications were then formed: BZDs, APs, ADs, psychotro-
pics (including BZDs, APs or ADs), Ops, AChs, AEs and
any CNS medications (including BZDs, APs, ADs, Ops,
AChs or AEs). Finally, 21 variables describing all combi-
nations of the CNS medications were formed.
Previously known risk factors of cognitive decline [20]
such as age, sex, basic education, hypertension, atrial
fibrillation or flutter, diabetes mellitus, congestive heart
disease and smoking at the baseline were used as con-
trol factors. Interviews were used in collecting data
about basic education and current smoking. Hyperten-
sion, diabetes and congestive heart disease were defined
according to clinical examination, medical history or
previous diagnoses in the medical records. The diagnosis
of atrial fibrillation or flutter was based on a diagnosis
in the medical records or on electrocardiograms (ECG)
recorded during the baseline examination.
Informed consent was obtained from all participants
or their caregivers in both phases of the study. The
study plans of the first and second Lieto studies were
approved by the Ethical Committee of the Hospital Dis-
trict of Southwest Finland.
Statistical analyses
The analyses were performed for the total population
and separately for men, women and younger (65-74 yrs)
and older (≥ 75 yrs) age groups. Participants who at the
beginning of the follow-up were using one type of the
CNS medications described in the methods and mea-
sures section were first compared with participants who
did not use any of these medications at baseline and
then with participants not using the medication con-
cerned. Participants using a combination of two or more
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pants using none of the CNS medications or their
combinations.
Chi-square and Fisher exact tests were used to test
differences in categorical variables between sexes, age
groups and, diagnoses as well as between medication
users and control groups at baseline and during the fol-
low-up examination. The significances of changes in
MMSE sum scores during the follow-up in the total
population and in all subgroups were tested using the
Wilcoxon signed rank test. The differences of the mean
MMSE sum scores, the mean ages and the mean num-
ber of medications and the changes of mean MMSE
sum scores between the groups were tested with the
Mann-Whitney U test. Associations between the use of
a certain group of CNS medications or the use of a
combination of CNS medications and the risk of cogni-
tive decline were first analyzed by the Mann-Whitney U
test. The significances of the differences in the changes
of cognitive functioning during the follow-up between
the users of a certain group of CNS medications or the
users of a combination of CNS medications and the cor-
responding control group of nonusers were first tested
with the Mann-Whitney U test. After these analyses,
adjusted analyses using the analysis of covariance were
performed for those groups in which the associations
between the use of a certain CNS medication or the
concomitant use of certain CNS medications and the
risk for cognitive decline were significant (p < 0.05) or
tended to be significant (0.05 < p < 0.10) in these bivari-
ate analyses. The associations of these variables (age,
sex, education, hypertension, atrial fibrillation or flutter,
diabetes mellitus, congestive heart disease and smoking
at baseline) with the decline in MMSE sum scores were
first analyzed in the total population, and only the vari-
ables that were significantly associated with decline
(higher age, p < 0.001, and congestive heart disease, p =
0.002) were adjusted in the analyses of covariance.
Results
Background data
The majority (n = 439; 77.7%) of the participants com-
pleting the follow-up were aged 64 to74 years at base-
line, and 126 (22.3%) were 75 years or older. The mean
age was 70.5 years (range 64 to 89).
Of the participants, 357 (63.2%) were married, 147
(26.0%) unmarried or divorced, and 61 (10.8%) widowed.
Altogether 393 participants (69.6%) lived at home with
another person or other people, 169 (29.9%) lived alone,
and 3 (0.5%) were institutionalized. 32 (5.7%) had
received less than basic education, 484 (85.7%) basic
education and 49 (8.7%) more than basic education. 523
(92.7%) were able to walk independently, 40 (7.1%) with
an assisting device, and 1 (0.2%) with the help of
another person. The mean number ± SD of prescribed
medications used regularly was 1.9 ± 2.2, and that of
medications used irregularly (as needed) was 0.6 ± 1.0.
Use of CNS medications
At baseline, 20% of the participants used BZDs and 14%
used AChs, while APs, ADs, Ops and AEs were used
only by some participants (Table 1). At least one CNS
medication was used by one third of the participants.
The use of BZDs was more common in women than in
men (25.1% vs. 13.2%, p < 0.001). The use of BZDs was
more common among the older age group than among
the younger one (34.1% vs. 16.4%, p < 0.001). APs were
also more commonly used by older participants com-
pared to the younger ones (8.7% vs. 3.9%, p = 0.027).
Women used CNS medications more commonly than
men (35.5% vs. 22.5%, p < 0.001), and the older age
group more commonly than the younger one (43.7% vs.
26.4%, p < 0.001). Varying according to the medication
group, 33 to 74% of participants used their medication
at both the baseline and follow-up examination.
The use of combinations of the CNS medications
included in the analyses was not common at baseline
(Table 2). The most common combinations were BZDs
and AChs (5.7% of the participants) and APs and AChs
(3.9%).
Changes in cognitive functioning during follow-up
During the follow-up period, cognitive functioning
declined significantly in the total population as well as
in all the subgroups (Table 3).
Background data and the use of CNS medications
The persons who used CNS medications also used more
other medications than the non-users (Table 4). Com-
pared to the group of non-users, the users of CNS med-
ications included more women, persons living alone,
persons needing tools for walking, and persons suffering
from depression, hypertension or transient ischemic
attacks.
CNS medications and their combinations and cognitive
change
One CNS medication
The users of at least one CNS medication were first
compared to those using no CNS medications. The sec-
ond control group consisted of non-users of the CNS
medications examined. The use of any kind of a CNS
medication at baseline was associated with cognitive
decline in the bivariate analysis (p = 0.041), but the rela-
tionship did not remain significant after adjusting for
control variables. The use of Ops at baseline was asso-
ciated with cognitive decline in the older age group, and
the use of AChs in men (Table 5). These relationships
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Medication Number of users
Baseline Follow-up Both baseline and follow-up
N % N % N % of users at baseline
Opioids 9 2 43 7 3 33
Anticholinergics 78 14 104 18 37 47
Antiepileptics 7 1 7 1 3 43
Benzodiazepines or related drugs 115 20 181 32 84 73
Antipsychotics 28 5 36 6 11 39
Antidepressants 19 3 71 13 14 74
At least one CNS medication 171 30 262 46 133 78
Number (%) of participants using CNS medication at the baseline and follow-up examinations and number of participants using these medications both at
baseline and during follow-up.
CNS = central nervous system
Table 2 Use of combinations of CNS medications
Combinations of medications Sex Age
Both Men Women 65-74 75+
(N = 565) (N = 227) (N = 338) (N = 439) (N = 126)
N%N%N%N%N%
Opioid and
anticholinergic 1 0.2 0 0 1 0.3 1 0.2 0 0
antiepileptic 0 000000000
benzodiazepine or related drug 4 0.7 0 0 4 1.2 1 0.2 3 2.4
antipsychotic 2 0.4 0 0 2 0.6 2 0.5 0 0
antidepressant 1 0.2 0 0 1 0.3 1 0.2 0 0
any of the above drugs 6 1.1 0 0 6 1.8 3 0.7 3 2.3
Anticholinergic and
antiepileptic 1 0.2 1 0.4 0 0 0 0 1 0.8
benzodiazepine or related drug 32 5.7 11 4.8 21 6.2 19 4.3 13 10.3
antipsychotic 22 3.9 6 2.6 16 4.7 13 3.0 9 7.1
antidepressant 9 1.6 3 1.3 6 1.8 8 1.8 1 0.8
any of the above drugs 48 8.5 15 6.6 33 9.8 31 7.1 17 13.5
Antiepileptic and
antidepressant 0 000000000
benzodiazepine or related drug 3 0.5 3 1.3 0 0 2 4.6 1 0.8
antipsychotic 1 0.2 1 0.4 0 0 0 0 1 0.8
any of the above drugs 3 0.5 3 1.3 0 0 2 0.5 1 0.8
Benzodiazepine or related drug and
antipsychotic 13 2.3 5 2.2 8 2.4 7 1.6 6 4.8
antidepressant 12 2.1 2 0.9 10 3.0 9 2.1 3 2.4
any of the above drugs 46 8.1 14 6.2 32 9.5 28 6.4 18 14.3
Antipsychotic and
antidepressant 5 0.9 1 0.4 4 1.2 3 0.7 2 1.6
any of the above drugs 28 5.0 7 3.1 21 6.2 17 3.9 11 8.7
Antidepressant and
any of the above drugs 19 3.4 4 1.8 15 4.4 15 3.4 4 3.2
Number and proportion of participants using a combination of CNS medications at baseline, by sex and age.
CNS = central nervous system
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variables.
Combinations of CNS medications
The combination of BZDs and Ops was associated with
cognitive decline among all participants and among
women. The association remained significant after
adjusting for control variables. The combination of Ops
and any CNS medication was associated with cognitive
decline among all participants. The association remained
significant after adjusting for control variables.
Discussion
Our results show that Ops and the combined use of
Ops and BZDs or any CNS medications were associated
with cognitive decline. In addition, we discovered that
the use of AChs was associated with the risk of cogni-
tive decline in men.
Strengths and limitations
The complete follow-up data were obtained for 565 par-
ticipants, and the material may be considered a middle-
sized cohort. The longitudinal population-based design
and a high participation rate (93% of the total aged
population) are major methodological strengths of this
study.
Medication history and clinical background data were
reliably recorded. The measure of cognitive functioning
(MMSE) is a frequently used instrument for assessing
global cognitive functioning. It measures general cogni-
tive performance. The MMSE cut off point 24/23 pro-
vides a sensitivity of 69% and a specificity of 99% for
dementia [21]. Only the persons who were cognitively
intact at baseline were included in the study population.
The diagnoses of the participants obtained from the
medical records of the health centre showed that cogni-
tive impairment was not diagnosed in any of the
participants using BZDs, APs, ADs, Ops, AChs or AEs
at baseline.
Many potential risk factors for cognitive decline such as
age, sex, education, hypertension, atrial fibrillation or flut-
ter, diabetes mellitus, congestive heart disease and smok-
ing at baseline could be adjusted for as control factors.
Even with adjustment, observational epidemiologic studies
can only show associations between risk factors and out-
come, whereas exploration of causalities requires a rando-
mized study design. However, long-lasting randomized
and controlled trials with exposure to harmful effects of
medications are not possible. Due to the observational,
longitudinal design and small sample sizes, these findings
cannot be directly generalized to an unselected ageing
population using Ops or AChs, but more studies among
elderly long-term Op or ACh users with larger sample
sizes are needed to confirm this association.
We adjusted the results for several potential risk factors
of cognitive decline, but were unable to use some medical
or other conditions (e.g., the use of alcohol) as adjusting
variables. The use of alcohol was not measured during
the first phase; therefore, we could not use this measure
as a control variable. Studies about the use of alcohol
among older Finns in the late 1980s have shown that the
use diminishes with increasing age, and few older people,
mainly men, are heavy users of alcohol [22].
The use of CNS medications was not common among
our participants, and the concomitant use of several
CNS medications was quite rare. These facts have
affected the strength of the statistical tests, especially
when analyzing the data by sex and age. Only baseline
medication data were used in the analyses. New medica-
tions may have been prescribed and previous ones may
have been given up during the follow-up period. Pre-
vious results have shown that psychotropics, especially
benzodiazepines, are commonly used for years
[14,15,23]. In our study, from one third to two thirds of
t h o s eu s i n gac e r t a i nC N Sm e d ication at baseline used
similar medication at the time of the follow-up examina-
tion. This supports the hypothesis that quite a few parti-
cipants used these medications during the whole follow-
up period and were real long-term users.
Results
T h eu s eo fO p sp r e d i c t e dc o g n i t i v ed e c l i n ed u r i n gt h e
long follow-up period. We have not found previous stu-
dies of possible long-term effects of Ops on cognitive
functioning in the aged. Ops used by our aged popula-
tion were codeine (N = 3), dextropropoxyphene (N = 2),
ethylmorphine (N = 2) and dextrometorphan (N = 2).
The diagnoses of the users of Ops showed that these
medications were used for painful arthrotic diseases.
Nobody was diagnosed to suffer from cancer pain.
Despite the small number of users of these medications,
Table 3 Cognitive functioning
Population MMSE sum
score
At baseline After 7.6-year
follow-up
p-
value
1
(1990-1991) (1998-1999)
Mean ± SD Mean ± SD
Total population (N =
565)
28.1 ± 1.9 26.1 ± 4.8 < 0.001
Men (N = 227) 28.3 ± 1.7 26.7 ± 3.4 < 0.001
Women (N = 338) 27.9 ± 2.0 25.7 ± 3.6 < 0.001
64-74 yrs (N = 439) 28.2 ± 1.8 26.9 ± 3.6 < 0.001
≥75 yrs (N = 126) 27.5 ± 2.0 23.3 ± 6.7 < 0.001
Cognitive functioning as measured by the Mini-Mental State Examination
(MMSE) at baseline and after a 7.6-year follow-up, by sex and age.
1significance of difference between baseline and follow-up, Wilcoxon signed
rank test
SD = standard deviation
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cognitive decline suggesting that the use of Ops has a
negative effect on cognitive functioning. The single use
of BZDs, ADs or APs was not related to the risk of
cognitive decline. These relationships are previously stu-
died mainly for the use of BZDs, and the results are
controversial [3-6,24,25]. Two small experimental rando-
mized, controlled studies showed no cognitive decline in
Table 4 Background data and the use of CNS medications
CNS medication users
(N = 171)
CNS medication non-users
(N = 394)
Background variable Mean ± SD Mean ± SD p-value
1
Age 71.9 ± 5.7 69.9 ± 4.9 < 0.001
Number of all medications 4.5 ± 2.7 1.6 ± 1.9 < 0.001
Number of regularly taken medications 3.3 ± 2.5 1.3 ± 1.7 < 0.001
Number of medications taken as needed 1.2 ± 1.2 0.3 ± 0.7 < 0.001
Number of all medications excluding CNS medications 3.2 ± 2.5 1.6 ± 1.9 < 0.001
Number of regularly taken medications excluding CNS medications 2.4 ± 2.1 1.3 ± 1.7 < 0.001
Number of medications taken as needed excluding CNS medications 0.8 ± 1.0 0.3 ± 0.7 < 0.001
N % N % p-value
2
Sex (woman) 120 70.2 218 55.3 < 0.001
Marital status
Married 15 8.8 46 11.7 0.076
Unmarried or divorced 101 59.1 256 65.0
Widowed 55 32.2 92 23.4
Place of living
At home alone 64 37.4 105 26.6 0.007
At home with other person 105 61.4 288 73.1
In institution or nursing home 2 1.2 1 0.3
Education
Less than basic 13 7.6 19 4.8 0.423
Basic 144 84.2 340 86.3
More than basic 14 8.2 35 8.9
Ability to walk
Independent 148 86.5 375 95.2 < 0.001
With tools 22 12.9 18 4.6
Needs to be assisted 0 0 1 0.3
Diagnoses
Depression 38 22.2 25 6.4 < 0.001
Alcohol related disease 1 0.6 5 1.3 0.673
Hypertension 59 34.5 100 25.4 0.027
Hypercholesterolemia 32 18.7 60 15.2 0.303
Diabetes mellitus (type I or II) 7 4.1 25 6.3 0.288
TIA 8 4.7 3 0.8 0.004
Cerebral infarct 1 0.6 3 0.8 1.000
Cerebral haemorrage 1 0.6 1 0.3 0.514
Cerebral trauma 2 1.2 4 1.0 1.000
Malignant tumour or cancer 5 0.3 17 4.3 0.432
HIV, lues or borreliosis 0 0 0 0 1.000
Dementia (all types) 2 1.2 0 0 0.091
Background data compared between the users and non-users of CNS medications, at baseline.
1significance of difference between users and non-users, Mann-Whitney U
2significance of difference between users and non-users, chi-square test or Fisher’s exact test
CNS = central nervous system
SD = standard deviation
TIA = transient ischaemic attack
HIV = human immunodeficiency virus
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[26,27]. In our study, the combination of BZDs or any
CNS medication and Ops was related to the risk of cog-
nitive decline. These findings support the idea that the
use of a psychotropic medication alone does not inevita-
bly effect cognitive functioning, but combining this kind
of a medication with Ops may be harmful.
The use of AChs was related to the risk of cognitive
decline in men. Here our results are in concordance
with the results of previous studies about the use of
AChs as a risk factor for cognitive decline among unse-
lected cognitively intact older persons [7-11]. In our
population, more men than women used anticholinergic
psychotropics with high CNS affinity [28], while women
used more commonly urge incontinence medications
targeted to have peripheral effects [28]. The blood-brain
barrier permeability of different anticholinergic medica-
tions may differ depending on molecules [28], age [29]
or disease states [30], which might explain why the risk
of cognitive deterioration was detected only among men.
The number of persons using two or more CNS medi-
cations concomitantly was small. This possesses statisti-
cal limitations. Negative results may be caused by the
rather small sample size and the small number of users.
Due to a lack of statistical power, negative results do
not prove that CNS medications are not related to the
risk of cognitive decline. Positive results, however, show
strong associations in this sample. In clinical settings,
the aged using these medications should be monitored
more carefully to detect the cognitive decline associated
to the use of the medications.
Conclusions
The use of anticholinergics and opioids alone and the
use of opioids with benzodiazepines or any psychotropic
medication or any CNS medication are associated with
cognitive decline in an older cognitively intact popula-
tion. However, studies with larger sample sizes and
about possible pathophysiologic mechanisms are needed.
Acknowledgements
The authors would like to thank ADP designers Jukka Saukkoriipi and Teemu
Kemppainen for their valuable work in performing the statistical analyses,
informatician Juha Hartikainen, MSc (Tech), and librarian Katri Haapaniemi for
assisting in performing searches in scientific literature, translator Liisa Punkka,
M.A., for proof-reading the manuscript, project secretary Selena Nitecki and
office secretary Ritva Kultalahti for their assistance in the writing process.
Table 5 Use of CNS medication and the change in cognitive functioning
Medication Sex Baseline MMSE MMSE during
follow-up
Change in MMSE
Users Controls Users Controls Users Controls
N Mean ±
SD
N Mean ±
SD
p1 Mean ±
SD
2
Mean ±
SD
2
p2 Mean ±
SD
Mean ±
SD
p for
diff
adjusted
p
Opioids
1 M
+W
9 27.7 ±
1.8
384 28.2 ±
1.8
0.276 21.2 ±
7.8
26.5 ±
4.5
0.011 -6.4 ±
7.3
-1.7 ±
4.3
0.007 0.032
Opioids
2 M
+W
9 27.7 ±
1.8
556 28.1 ±
1.9
0.372 21.2 ±
7.8
26.2 ±
4.7
0.018 -6.4 ±
7.3
-1.9 ±
4.4
0.009 0.021
Anticholinergics
2 M 29 28.2 ±
1.8 ±
198 28.3 ±
1.7
0.938 25.0 ±
4.4
27.0 ±
3.2
0.015 -3.2 ±
4.0
-1.3 ±
2.9
0.021 0.002
Opioid and
any other CNS
medication
1
M
+W
6 27.3 ±
2.0
384 28.2 ±
1.8
0.020 18.8 ±
8.7
26.5 ±
4.5
0.010 -8.5 ±
8.0
-1.7 ±
4.3
0.004 0.007
Benzodiazepine or related
drug and
opioid
1 M
+W
4 26.5 ±
1.7
384 28.2 ±
1.8
0.052 15.8 ±
8.7
26.5 ±
4.5
0.004 -10.8 ±
9.0
-1.7 ±
4.3
0.006 0.002
opioid
1 W 4 26.5 ±
1.7
210 28.0 ±
2.0
0.097 15.8 ±
8.7
26.0 ±
5.2
0.007 -10.8 ±
9.0
-2.0 ±
5.1
0.010 0.024
Significant associations between the use of at least one CNS medication or the use of a combination of CNS medications and change in cognitive functioning
(MMSE) during the follow-up of 7.6 years (1990-1999), by sex.
M = men
W = women
MMSE = Mini-Mental State Examination
SD = standard deviation
p1 = significance of difference in MMSE at baseline between users and controls, Mann-Whitney U test
p2 = significance of difference in MMSE during follow-up examination between users and control, Mann-Whitney U test
p for diff = significance of difference of change in MMSE between users and controls, Mann-Whitney U test
adjusted p = p-value for difference of change in MMSE between users and controls adjusted for control factors, analysis of covariance
1control group: no medication with effects on the central nervous system
2control group: non-users of corresponding medications
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